公开(公告)号：US20200331859A1

公开(公告)日：2020-10-22

申请号：US16920155

申请日：2020-07-02

Applicant: AMGEN INC. ,  CYTOKINETICS, INC.

Inventor： Sheng Cui ,  Henry Morrison ,  Karthik Nagapudi ,  Shawn Walker ,  Charles Bernard ,  Karl Bennett Hansen ,  Neil Fred Langille ,  Alan Martin Allgeier ,  Steven Mennen ,  Jacqueline C.S. Woo ,  Bradley Paul Morgan ,  Alex Muci

IPC: C07D213/75 ,  A61K9/20 ,  A61K31/496 ,  A61K47/38

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

公开(公告)号：US20160016906A1

公开(公告)日：2016-01-21

申请号：US14773436

申请日：2014-03-14

Applicant: AMGEN INC. ,  CYTOKINETICS, INC.

Inventor： Sheng Cui ,  Henry Morrison ,  Karthik Nagapudi ,  Shawn Walker ,  Charles Bernard ,  Karl Bennett Hansen ,  Neil Fred Langille ,  Alan Martin Allgeier ,  Steven Mennen ,  Jacqueline Woo ,  Bradley Paul Morgan ,  Alex Muci

IPC: C07D213/75

CPC classification number: C07D213/75 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/496 ,  A61K47/38

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use. Omecamtiv mecarbil (AMG 423, CK-1827452), having the structure:

Abstract translation: 本发明提供了奥美康米卡非二盐酸盐形式，其组合物和药物制剂及其制备和使用方法。 Omecamtiv mecarbil（AMG 423，CK-1827452），具有以下结构：

公开(公告)号：US11472773B2

公开(公告)日：2022-10-18

申请号：US16920144

申请日：2020-07-02

Applicant: AMGEN INC. ,  CYTOKINETICS, INC.

Inventor： Sheng Cui ,  Henry Morrison ,  Karthik Nagapudi ,  Shawn D. Walker ,  Charles Bernard ,  Karl Bennett Hansen ,  Neil Fred Langille ,  Alan Martin Allgeier ,  Steven Mennen ,  Jacqueline C. S. Woo ,  Bradley Paul Morgan ,  Alex Muci

IPC: A61P9/00 ,  A61P9/04 ,  C07D213/75 ,  A61K47/38 ,  A61K31/496 ,  A61K9/20

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

公开(公告)号：US20200079736A1

公开(公告)日：2020-03-12

申请号：US16684216

申请日：2019-11-14

Applicant: AMGEN INC. ,  CYTOKINETICS, INC.

Inventor： Sheng Cui ,  Henry Morrison ,  Karthik Nagapudi ,  Shawn Walker ,  Charles Bernard ,  Karl Bennett Hansen ,  Neil Fred Langille ,  Alan Martin Allgeier ,  Steven Mennen ,  Jacqueline C.S. Woo ,  Bradley Paul Morgan ,  Alex Muci

IPC: C07D213/75 ,  A61K47/38 ,  A61K31/496 ,  A61K9/20

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

公开(公告)号：US20180312469A1

公开(公告)日：2018-11-01

申请号：US15963529

申请日：2018-04-26

Applicant: AMGEN INC. ,  CYTOKINETICS, INC.

Inventor： Sheng Cui ,  Henry Morrison ,  Karthik Nagapudi ,  Shawn Walker ,  Charles Bernard ,  Karl Bennett Hansen ,  Neil Fred Langille ,  Alan Martin Allgeier ,  Steven Mennen ,  Jacqueline Woo ,  Bradley Paul Morgan ,  Alex Muci

IPC: C07D213/75 ,  A61K9/20 ,  A61K31/496 ,  A61K47/38

CPC classification number: C07D213/75 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/496 ,  A61K47/38

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

公开(公告)号：US20210198203A1

公开(公告)日：2021-07-01

申请号：US17200174

申请日：2021-03-12

Applicant: CYTOKINETICS, INC.

Inventor： Bradley Paul Morgan ,  Alex Muci ,  Pu-Ping Lu ,  Erica Anne Kraynack ,  Todd Tochimoto ,  David J. Morgans, JR.

IPC: C07D213/75 ,  C07D211/56 ,  C07D239/42 ,  C07D261/14 ,  C07D263/48 ,  C07D271/113 ,  C07D295/26 ,  C07D401/10 ,  C07D401/12 ,  C07D417/10 ,  C07D487/04 ,  C07D491/04 ,  C07D513/04 ,  C07D417/00 ,  C07D417/12

Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

公开(公告)号：US10766899B2

公开(公告)日：2020-09-08

申请号：US14246230

申请日：2014-04-07

Applicant: Cytokinetics, Inc.

Inventor： Bradley P. Morgan ,  David J. Morgans, Jr. ,  Alex Muci

IPC: C07D241/38 ,  C07D487/04 ,  C07D519/00

Abstract: Provided are methods of preparing compounds of Formula 201:

公开(公告)号：US08871768B2

公开(公告)日：2014-10-28

申请号：US13897086

申请日：2013-05-17

Applicant: Cytokinetics, Inc.

Inventor： Bradley P. Morgan ,  David J. Morgans ,  Alex Muci ,  Pu-Ping Lu ,  Erica A. Kraynack ,  Todd Tochimoto

IPC: A61K31/497 ,  A61K31/5377 ,  A61K31/4965 ,  A61K31/496 ,  C07D213/75

CPC classification number: C07D213/75 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/5377

Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Abstract translation: 某些取代的脲衍生物选择性地调节心肌肉瘤，例如通过增强心肌肌球蛋白，并且可用于治疗包括充血性心力衰竭的收缩性心力衰竭。

公开(公告)号：US20190352267A1

公开(公告)日：2019-11-21

申请号：US16459754

申请日：2019-07-02

Applicant: CYTOKINETICS, INC.

Inventor： Bradley Paul Morgan ,  Alex Muci ,  Pu-Ping Lu ,  Erica Anne Kraynack ,  Todd Tochimoto ,  David J. Morgans, JR.

IPC: C07D213/75 ,  C07D417/00 ,  C07D417/12 ,  C07D513/04 ,  C07D491/04 ,  C07D487/04 ,  C07D417/10 ,  C07D211/56 ,  C07D401/10 ,  C07D295/26 ,  C07D271/113 ,  C07D263/48 ,  C07D261/14 ,  C07D239/42 ,  C07D401/12

Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

公开(公告)号：US08653081B2

公开(公告)日：2014-02-18

申请号：US13853352

申请日：2013-03-29

Applicant: Cytokinetics, Inc.

Inventor： Bradley P. Morgan ,  Erica A. Kraynack ,  Pu-Ping Lu ,  Alex Muci ,  David J. Morgans

IPC: A61K31/496 ,  C07D413/14

CPC classification number: C07D413/12 ,  C07D213/75 ,  C07D295/13 ,  C07D295/145 ,  C07D401/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Abstract translation: 某些取代的脲衍生物选择性地调节心肌肉瘤，例如通过增强心肌肌球蛋白，并且可用于治疗包括充血性心力衰竭的收缩性心力衰竭。